Number of qualified clients: CDEC talked over the uncertainty in the number of individuals with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who're labeled as owning gentle or moderate condition could have a critical bleeding phen